More recently, experiments conducted in Ewing sarcoma cells have demonstrated that IGF1R upregulation promotes resistance to CDK4/6 inhibitors suggesting that dual targeting of CDK4/6 and IGF1R may represent a synergistic combination with potential clinical implications for therapy in this disease [84]. This evidence concerns the gene IGF1R and Ewing sarcoma.